Physician profile
Ashley Riegert
NPI 1992438378
$1,638.40
in general payments reported to CMS, 2019-2025
19 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.72 · 2023: $787 · 2024: $379 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $426.82 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $176.20 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $152.03 | 2023 | Xarelto |
| Abiomed | $142.82 | 2024 | Impella |
| Boston Scientific Corporation | $142.60 | 2022-2025 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $121.17 | 2023 | |
| Pfizer INC. | $82.10 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $64.48 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $46.66 | 2022-2024 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.62 | 2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $37.30 | 2025 | Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.64 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $32.39 | 2023-2025 | Farxiga |
| Scpharmaceuticals INC. | $25.84 | 2025 | |
| Biosense Webster, INC. | $24.30 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $21.72 | 2025 | Evkeeza, Praluent |
| E.R. Squibb & Sons, L.L.C. | $21.64 | 2025 | Camzyos |
| Csl Behring | $20.84 | 2023 | Kcentra |
| Novo Nordisk INC | $18.23 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Riegert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.